Lower urinary tract symptoms associated with benign prostatic hyperplasia: Combined treatment with fesoterodine fumarate extended-release and tamsulosin - A prospective study

Urologia Internationalis

Volumn 90, Issue 2, 2013, Pages 156-160

  Konstantinidis, Charalampos ^a   Samarinas, Michael ^b   Andreadakis, Sotirios ^c   Xanthis, Stylianos ^b   Skriapas, Konstantinos ^b  

^a National Institute of Rehabilitation   (Greece)

^b General Hospital of Larisa   (Greece)

^c General Clinic   (Greece)

Author keywords

Blocker; Anticholinergics; Lower urinary tract symptoms; Overactive bladder; Prostate

Indexed keywords

FESOTERODINE; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION DISORDER; MONOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; URINE RETENTION; XEROSTOMIA;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SULFONAMIDES; URINARY TRACT;

EID: 84874482191     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345050     Document Type: Article

References (18)

1. Fitzpatrick JM: The natural history of benign prostatic hyperplasia. BJU Int 2006; 97: 3-6
2. De Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C: The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003; 169: 535-539
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49
4. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-1314
5. Bruskewitz RC: Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003; 5: 72-80
6. Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: Bladder, outlet, or both? Curr Urol Rep 2002; 3: 445-451
7. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006; 49: 651-658
8. Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter SS: Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 2004; 94: 1283-1296
9. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-552
10. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006; 296: 2319-2328
11. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
12. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: Effects of prostate size. Eur Urol 2009; 55: 472-479
13. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α -blockers. Eur Urol 2009; 56: 534-541
14. MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW, Nitti VW: Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: Randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83: 1002-1010
15. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an α -blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J Urol 2003; 169: 2253-2256
16. Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z: Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α -blocker treatment for lower urinary tract symptoms. BJU Int 2012; 109: 1831-1840
17. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-820
18. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557